S. Walker

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Steven Walker, Stephen Walker, S.m. Walker, Steven M. Walker, Steve M. Walker, Steven M Walker, Steven Michael Walker
Publication record
65 papers · 1,671 citations · H-index 15

PAPERS

337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials
20220 citationsauthor #7
Abstract 152: A machine learning approach to detect FFPE artefacts leads to accurate estimation of tumor mutational burden from sequencing data without a matched normal
20210 citationsauthor #5
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer
202132 citationsauthor #6
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer
20210 citationsauthor #6
Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma
202018 citationsauthor #5
ATM Kinase Inhibition Preferentially Sensitises PTEN-Deficient Prostate Tumour Cells to Ionising Radiation
20209 citationsauthor #3
Targeting CXCR1 and CXCR2 to overcome radiotherapy resistance in PTEN-deficient prostate carcinoma
20202 citationsauthor #5
Abstract P1-10-17: cGAS-STING driven immune activation predicts response to neoadjuvant chemotherapy and suggests rational IO combination therapies: Results of the Neo-DDIR study
20200 citationsauthor #5
Identification of cancer hallmarks associated with benefit in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade.
20200 citationsauthor #14
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer
202021 citationsauthor #9
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning
2020200 citationsauthor #16
Translational analysis of esophageal adenocarcinoma (EAC) patients treated with oxaliplatin and capecitabine (Xelox) +/- the dual ErbB inhibitor AZD8931 in the DEBIOC study.
20202 citationsauthor #5
Abstract P3-11-12: Biomarker phase neo-DDRD trial: Predicting response to neoadjuvant chemotherapy (NAC) in early breast cancer using the DNA damage repair deficiency (DDRD) assay
20190 citationsauthor #4
Abstract 4446: Assessment of tissue composition with digital pathology in colorectal cancer
20193 citationsauthor #10
Biometric Selection: Body Parts Online
20190 citationsauthor #1
Consensus gene expression analysis to identify key hallmarks of cancer in malignant melanoma.
20190 citationsauthor #7
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
201925 citationsauthor #13
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
201941 citationsauthor #6
SANS Institute Information Security Reading Room Biometric Selection : Body Parts Online
20190 citationsauthor #1
Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning
201915 citationsauthor #16
Abstract 283: Identification of a high-risk subgroup in primary prostate cancers presenting with targetable immune biology
20182 citationsauthor #3
Exploration of the cGAS-STING pathway in prostate cancer.
20182 citationsauthor #3
Radio-resistance of PTEN-deficient prostate tumours is enhanced by treatment-induced chemokine signalling and is associated with biochemical recurrence and development of metastasis.
20180 citationsauthor #9
Abstract 578: Loss of MED12 predicts for a DNA damage repair deficiency phenotype and activates immune signalling via the STING pathway
20181 citationsauthor #4
Abstract B035: Radio-resistance of PTEN-deficient prostate tumors is enhanced by treatment-induced chemokine signaling and is associated with biochemical recurrence and development of metastasis
20180 citationsauthor #10
Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue
20180 citationsauthor #8
A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment.
20172 citationsauthor #3
OC-0126: A gene expression assay to predict the risk of distant metastases in localized prostate cancer
20170 citationsauthor #3
A Metastatic Biology Gene Expression Assay to Predict the Risk of Distant Metastases in Patients With Localized Prostate Cancer Treated With Primary Radical Treatment
20170 citationsauthor #3
Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313).
20172 citationsauthor #5
Enhanced radio-sensitivity of PTEN-deficient prostate tumours mediated by inhibition of intrinsic and treatment-potentiated CXC-chemokine signaling
20172 citationsauthor #10
Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial
20170 citationsauthor #5
Association of a DNA damage response deficiency (DDRD) assay with prognosis in resected esophageal and gastric adenocarcinoma.
20170 citationsauthor #8
Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy
2017100 citationsauthor #3
Association of a specific innate immune response to DNA damage with DNA repair deficient colorectal cancers.
20166 citationsauthor #3
An innate immune response to intrinsic DNA damage predicts resistance to docetaxel in prostate cancer
20161 citationsauthor #2
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
2016415 citationsauthor #2
Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line
201623 citationsauthor #4
When the guardian becomes the enemy: Targeting ATM in PTEN-deficient cancers
20166 citationsauthor #2
Abstract 4000: A DNA damage response deficiency (DDRD) group in breast cancer is associated with activation of the STING innate immune pathway and PD-L1 expression
20161 citationsauthor #2
STAT3 regulated ARF expression suppresses prostate cancer metastasis
2015158 citationsauthor #5
Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.
201568 citationsauthor #3
Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis
20155 citationsauthor #5
Abstract C105: DNA damage response deficiency (DDRD) in breast cancer is associated with a STING-dependent innate immune response
20152 citationsauthor #2
ID: 263: Loss of IL-6/Stat3 signalling drives metastatic prostate cancer in mice and men
20150 citationsauthor #5
Investigation of the Kv channel inhibitor, 4-aminopyridine, on proliferation, survival and migration of human prostate cancer cells
20140 citationsauthor #3
Functional expression of TRPM8 channels in normal prostate and prostate cancer cell lines
20140 citationsauthor #2
Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer
2014108 citationsauthor #15
Abstract 3138: IL-6/Stat3 signaling is an indispensable modulator of oncogene-induced cellular senescence
20140 citationsauthor #7
Investigation of BK channels and the KCNMA1 subunit in normal prostate and prostate cancer cell lines
20140 citationsauthor #4
Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.
201384 citationsauthor #3
Abstract C215: Sensitivity of PTEN-deficient prostate carcinoma xenografts to ionizing radiation through inhibition of treatment-induced CXCL8 signaling.
20130 citationsauthor #3
A PROGNOSTIC SIGNATURE FOR PTEN-DEFICIENT GLIOBLASTOMAS
20120 citationsauthor #4
Activation of and dependence on ataxia telangiectasia mutated kinase in PTEN-deficient tumor cells
20120 citationsauthor #2
Abstract 4820: Identification of a metagene representing SRC activation which is predictive of response to Dasatinib
20120 citationsauthor #4
An evaluation of siRNA screening in identification of targets in PTEN deficient tumor cells.
20113 citationsauthor #2
P5-01-12: Identification of an ATM Activation Subtype in PTEN Mutant Breast Tumours.
20110 citationsauthor #2
PP 74 A subtype representing activated ATM signalling in PTEN-null tumours
20110 citationsauthor #2
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.
2011191 citationsauthor #18
Abstract 250: The critical requirement of ATM function in PTEN null cell lines
20110 citationsauthor #2
New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC).
20102 citationsauthor #5
Abstract 1153: The development and utilization of a novel DNA microarray platform for biomarker and target identification in advanced prostate cancer
20100 citationsauthor #1
Genomic signature of prognosis for Stage II colorectal cancer from FFPE tissue
20070 citationsauthor #5
Elevated caspase-3 expression is an early event in PDT-induced apoptosis in human skin.
20040 citationsauthor #5
Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids.
2003120 citationsauthor #3

TIMELINE

2003 120 citations

2004 0 citations

2007 0 citations

2010 2 citations

2011 194 citations

2012 0 citations

2013 84 citations

2014 108 citations

2015 233 citations

2016 452 citations

2017 106 citations

2018 5 citations

2019 84 citations

2020 252 citations

2021 32 citations

2022 0 citations

COAUTHOR MAP

CONCEPT FOOTPRINT